BIOMAT Database Logo BIOMAT Database Logo

An aldose reductase inhibitor, TAT, prevents electroretinographic abnormalities and ADP-induced hyperaggregability in streptozotocin-induced diabetic rats. 1995

N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and Y Hamada, and T Hara, and N Takeuchi, and S Inukai, and N Kasama, and H Fukasawa
The Third Department of Internal Medicine, Nagoya University School of Medicine, Japan.

Rats with streptozotocin-induced diabetes were oral given TAT, a potent aldose reductase inhibitor, at a dose of 10 mg kg-1 day-1 or 40 mg kg-1 day-1 for 30 days. Prolongation of the peak latency of oscillatory potentials in the b-wave of the electroretinogram (ERG), which is associated with retinal Müller cell dysfunction, was significantly improved by treatment with TAT as compared with untreated diabetic rats [sigma(O1 + O2 + O3) was 106.8 +/- 1.8 ms in normal controls (NC), 118.2 +/- 1.1 ms in diabetic controls (DC) (P < 0.001 vs. NC), 110.8 +/- 1.5 ms with 10 mg kg-1 TAT (P < 0.001 vs. DC) and 111.4 +/- 1.6 ms with 40 mg kg-1 TAT (P < 0.01 vs. DC)]. The improvement in ERG abnormalities in diabetic rats was accompanied by partial reduction of elevated sorbitol levels in the retina and erythrocytes, and by correction of platelet hyperaggregability. The authors' findings suggest that a better understanding of the mechanism by which TAT acts may provide new insights into the pathogenesis of hyperglycaemic retinal dysfunction and contribute to establishing effective therapy for diabetic retinopathy.

UI MeSH Term Description Entries
D008297 Male Males
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D012160 Retina The ten-layered nervous tissue membrane of the eye. It is continuous with the OPTIC NERVE and receives images of external objects and transmits visual impulses to the brain. Its outer surface is in contact with the CHOROID and the inner surface with the VITREOUS BODY. The outer-most layer is pigmented, whereas the inner nine layers are transparent. Ora Serrata
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D003930 Diabetic Retinopathy Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION. Diabetic Retinopathies,Retinopathies, Diabetic,Retinopathy, Diabetic
D004596 Electroretinography Recording of electric potentials in the retina after stimulation by light. Electroretinographies
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005632 Fructose A monosaccharide in sweet fruits and honey that is soluble in water, alcohol, or ether. It is used as a preservative and an intravenous infusion in parenteral feeding. Levulose,Apir Levulosa,Fleboplast Levulosa,Levulosa,Levulosa Baxter,Levulosa Braun,Levulosa Grifols,Levulosa Ibys,Levulosa Ife,Levulosa Mein,Levulosado Bieffe Medit,Levulosado Braun,Levulosado Vitulia,Plast Apyr Levulosa Mein,Levulosa, Apir,Levulosa, Fleboplast
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D000244 Adenosine Diphosphate Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position. ADP,Adenosine Pyrophosphate,Magnesium ADP,MgADP,Adenosine 5'-Pyrophosphate,5'-Pyrophosphate, Adenosine,ADP, Magnesium,Adenosine 5' Pyrophosphate,Diphosphate, Adenosine,Pyrophosphate, Adenosine

Related Publications

N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and Y Hamada, and T Hara, and N Takeuchi, and S Inukai, and N Kasama, and H Fukasawa
An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy.
December 1995, The Journal of laboratory and clinical medicine,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and Y Hamada, and T Hara, and N Takeuchi, and S Inukai, and N Kasama, and H Fukasawa
Characterization of a novel aldose reductase inhibitor, TAT, and its effects on streptozotocin-induced diabetic neuropathy in rats.
March 1993, Japanese journal of pharmacology,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and Y Hamada, and T Hara, and N Takeuchi, and S Inukai, and N Kasama, and H Fukasawa
Effects of an aldose reductase inhibitor on gastroenteropathy in streptozotocin-diabetic rats.
November 2003, Diabetes research and clinical practice,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and Y Hamada, and T Hara, and N Takeuchi, and S Inukai, and N Kasama, and H Fukasawa
Tolrestat, an aldose reductase inhibitor, prevents nerve dysfunction in conscious diabetic rats.
April 1987, Diabetes,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and Y Hamada, and T Hara, and N Takeuchi, and S Inukai, and N Kasama, and H Fukasawa
Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.
November 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and Y Hamada, and T Hara, and N Takeuchi, and S Inukai, and N Kasama, and H Fukasawa
Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.
March 1984, Metabolism: clinical and experimental,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and Y Hamada, and T Hara, and N Takeuchi, and S Inukai, and N Kasama, and H Fukasawa
Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats.
November 1995, Diabetes research and clinical practice,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and Y Hamada, and T Hara, and N Takeuchi, and S Inukai, and N Kasama, and H Fukasawa
Effects of aldose reductase inhibitor on retinal microangiopathy in streptozotocin-diabetic rats.
January 1985, Japanese journal of ophthalmology,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and Y Hamada, and T Hara, and N Takeuchi, and S Inukai, and N Kasama, and H Fukasawa
Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats.
March 2003, Diabetes,
N Hotta, and N Koh, and F Sakakibara, and J Nakamura, and Y Hamada, and T Hara, and N Takeuchi, and S Inukai, and N Kasama, and H Fukasawa
Thirteen-month inhibition of aldose reductase by zenarestat prevents morphological abnormalities in the dorsal root ganglia of streptozotocin-induced diabetic rats.
January 2009, Brain research,
Copied contents to your clipboard!